Chengdu Easton Biopharmaceuticals Co Ltd (688513) - Net Assets
Based on the latest financial reports, Chengdu Easton Biopharmaceuticals Co Ltd (688513) has net assets worth CN¥3.09 Billion CNY (≈ $451.57 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.78 Billion ≈ $552.76 Million USD) and total liabilities (CN¥691.49 Million ≈ $101.19 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Chengdu Easton Biopharmaceuticals Co Ltd tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.09 Billion |
| % of Total Assets | 81.69% |
| Annual Growth Rate | 35.85% |
| 5-Year Change | 190.79% |
| 10-Year Change | 1609.6% |
| Growth Volatility | 59.89 |
Chengdu Easton Biopharmaceuticals Co Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Chengdu Easton Biopharmaceuticals Co Ltd's net assets have evolved over time, based on quarterly financial data. See Chengdu Easton Biopharmaceuticals Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)
The table below shows the annual net assets of Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2025. For live valuation and market cap data, see Chengdu Easton Biopharmaceuticals Co Ltd (688513) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.66 Billion ≈ $975.13 Million |
+147.00% |
| 2024-12-31 | CN¥2.70 Billion ≈ $394.79 Million |
+3.63% |
| 2023-12-31 | CN¥2.60 Billion ≈ $380.96 Million |
+6.50% |
| 2022-12-31 | CN¥2.44 Billion ≈ $357.70 Million |
+6.67% |
| 2021-12-31 | CN¥2.29 Billion ≈ $335.34 Million |
+9.37% |
| 2020-12-31 | CN¥2.10 Billion ≈ $306.60 Million |
+200.42% |
| 2019-12-31 | CN¥697.44 Million ≈ $102.06 Million |
+19.80% |
| 2018-12-31 | CN¥582.19 Million ≈ $85.19 Million |
+30.75% |
| 2017-12-31 | CN¥445.28 Million ≈ $65.16 Million |
+14.24% |
| 2016-12-31 | CN¥389.79 Million ≈ $57.04 Million |
+45.33% |
| 2015-12-31 | CN¥268.21 Million ≈ $39.25 Million |
+31.96% |
| 2014-12-31 | CN¥203.25 Million ≈ $29.74 Million |
+20.54% |
| 2013-12-31 | CN¥168.62 Million ≈ $24.67 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chengdu Easton Biopharmaceuticals Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2664.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.33 Billion | 46.43% |
| Other Comprehensive Income | CN¥2.87 Billion | 100.00% |
| Total Equity | CN¥2.87 Billion | 100.00% |
Chengdu Easton Biopharmaceuticals Co Ltd Competitors by Market Cap
The table below lists competitors of Chengdu Easton Biopharmaceuticals Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TTW Public Company Limited
BK:TTW
|
$1.16 Billion |
|
Jutze Intelligent Technology Co Ltd
SHE:300802
|
$1.16 Billion |
|
Red Star Macalline Group Corp Ltd Class A
SHG:601828
|
$1.16 Billion |
|
Kestra Medical Technologies, Ltd. Common Stock
NASDAQ:KMTS
|
$1.16 Billion |
|
Aurisco Pharmaceutical Co Ltd
SHG:605116
|
$1.16 Billion |
|
Pennant Group Inc
NASDAQ:PNTG
|
$1.16 Billion |
|
Reit 1
TA:RIT1
|
$1.16 Billion |
|
Corbion NV
AS:CRBN
|
$1.16 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chengdu Easton Biopharmaceuticals Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,697,921,576 to 2,865,981,000, a change of 168,059,424 (6.2%).
- Net income of 283,248,300 contributed positively to equity growth.
- Dividend payments of 76,787,845 reduced retained earnings.
- Other comprehensive income increased equity by 2,765,116,000.
- Other factors decreased equity by 2,803,517,031.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥283.25 Million | +9.88% |
| Dividends Paid | CN¥76.79 Million | -2.68% |
| Other Comprehensive Income | CN¥2.77 Billion | +96.48% |
| Other Changes | CN¥-2.80 Billion | -97.82% |
| Total Change | CN¥- | 6.23% |
Book Value vs Market Value Analysis
This analysis compares Chengdu Easton Biopharmaceuticals Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.73x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 34.41x to 2.73x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥1.31 | CN¥45.01 | x |
| 2014-12-31 | CN¥1.53 | CN¥45.01 | x |
| 2015-12-31 | CN¥1.92 | CN¥45.01 | x |
| 2016-12-31 | CN¥4.49 | CN¥45.01 | x |
| 2017-12-31 | CN¥3.37 | CN¥45.01 | x |
| 2018-12-31 | CN¥4.40 | CN¥45.01 | x |
| 2019-12-31 | CN¥5.29 | CN¥45.01 | x |
| 2020-12-31 | CN¥14.24 | CN¥45.01 | x |
| 2021-12-31 | CN¥13.01 | CN¥45.01 | x |
| 2022-12-31 | CN¥13.83 | CN¥45.01 | x |
| 2023-12-31 | CN¥14.71 | CN¥45.01 | x |
| 2024-12-31 | CN¥15.40 | CN¥45.01 | x |
| 2025-12-31 | CN¥16.49 | CN¥45.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chengdu Easton Biopharmaceuticals Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.88%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 21.27%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.33x
- Recent ROE (9.88%) is below the historical average (12.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 9.36% | 9.07% | 0.64x | 1.62x | CN¥-1.01 Million |
| 2014 | 15.60% | 14.00% | 0.74x | 1.51x | CN¥10.50 Million |
| 2015 | 15.40% | 15.63% | 0.77x | 1.28x | CN¥13.19 Million |
| 2016 | 14.70% | 16.92% | 0.65x | 1.33x | CN¥18.34 Million |
| 2017 | 14.46% | 13.51% | 0.80x | 1.33x | CN¥19.84 Million |
| 2018 | 23.19% | 17.56% | 0.97x | 1.36x | CN¥76.80 Million |
| 2019 | 15.57% | 11.47% | 0.96x | 1.42x | CN¥38.87 Million |
| 2020 | 8.50% | 19.33% | 0.36x | 1.21x | CN¥-31.36 Million |
| 2021 | 10.14% | 22.72% | 0.37x | 1.21x | CN¥3.26 Million |
| 2022 | 10.08% | 21.06% | 0.39x | 1.23x | CN¥2.07 Million |
| 2023 | 8.70% | 20.28% | 0.33x | 1.29x | CN¥-33.77 Million |
| 2024 | 8.83% | 17.65% | 0.40x | 1.26x | CN¥-31.56 Million |
| 2025 | 9.88% | 21.27% | 0.35x | 1.33x | CN¥-3.35 Million |
Industry Comparison
This section compares Chengdu Easton Biopharmaceuticals Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $604,930,526
- Average return on equity (ROE) among peers: 13.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chengdu Easton Biopharmaceuticals Co Ltd (688513) | CN¥3.09 Billion | 9.36% | 0.22x | $1.16 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $85.02 Million | 26.56% | 2.79x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $64.35 Million | 12.98% | 2.10x | $1.50 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $378.62 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $730.78 Million | -9.68% | 0.13x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $94.10 Million | 30.66% | 1.57x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $626.21 Million | 14.40% | 0.46x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $170.01 Million | 48.10% | 0.80x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $238.05 Million | 18.81% | 2.12x | $496.75 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.26 Billion | 16.10% | 0.32x | $1.64 Billion |
About Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; A… Read more